Restless legs syndrome

That this House recognises the significant impact of restless legs syndrome (RLS), also known as Willis-Ekbom disease, which affects up to 10% of the UK population; notes with concern that current NICE guidelines do not reflect the increasing clinical evidence regarding the risks associated with dopamine agonists, including the growing incidence of impulse control disorders such as gambling addiction and hypersexuality; acknowledges the economic and personal toll of untreated or misdiagnosed RLS on individuals and the NHS; supports the call by the charity RLS UK for a revision of the NICE guidelines to ensure they reflect modern best practice and patient experience; calls for improved training for general practitioners to support early diagnosis and safer treatment options; and urges the Government to work with RLS UK and relevant stakeholders to update policy and clinical guidelines, ensuring better outcomes for those affected by this debilitating condition.